<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Griseofulvin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Griseofulvin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Griseofulvin: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8502" href="/d/html/8502.html" rel="external">see "Griseofulvin: Drug information"</a> and <a class="drug drug_patient" data-topicid="12519" href="/d/html/12519.html" rel="external">see "Griseofulvin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1047635"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antifungal Agent, Systemic</span></li></ul></div>
<div class="block dop drugH1Div" id="F177541"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing; susceptible infection </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2018','lexi-content-ref-AAP.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2018','lexi-content-ref-AAP.2018'])">Ref</a></span>): Children &gt;2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Microsize: Oral: 20 to 25 mg/kg/day in single or 2 divided doses; maximum daily dose: 1,000 mg/<b>day </b></p>
<p style="text-indent:-2em;margin-left:4em;">Ultramicrosize: Oral: 10 to 15 mg/kg/day once daily; maximum daily dose: 750 mg/<b>day</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2b44e72-c508-46fe-b538-5b3b685f7a46">Tinea capitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea capitis:</b>
<b>Note: </b>Preferred therapy for <i>Microsporum canis</i> infection; may be used in combination with adjunctive topical therapy (eg, selenium or antifungal shampoo) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2018'])">Ref</a></span>). Patients receiving doses on the lower end of the dose range may require longer durations of treatment for fungal eradication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23575220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23575220'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;1 month to Children ≤2 years: Limited data available: Oral: Microsize: 15 to 25 mg/kg/day in single or 2 divided doses (maximum daily dose: 1,000 mg/<b>day</b>) until resolution; usually 6 to 8 weeks duration, although resistant cases may require longer duration; tinea capitis is rare in ages &lt;1 year, infant dosing based on small case-series/reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Atanasovski.2011','lexi-content-ref-25234064','lexi-content-ref-27502503','lexi-content-ref-19487765','lexi-content-ref-22468173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Atanasovski.2011','lexi-content-ref-25234064','lexi-content-ref-27502503','lexi-content-ref-19487765','lexi-content-ref-22468173'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Microsize: Oral: 20 to 25 mg/kg/day in single daily dose or in 2 divided doses (maximum daily dose: 1,000 mg/<b>day</b>) for 6 to 8 weeks or until fungal cultures clear; in some cases, treatment up to 12 to 18 weeks may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25403034','lexi-content-ref-25234064','lexi-content-ref-27502503','lexi-content-ref-20609140','lexi-content-ref-AAP.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25403034','lexi-content-ref-25234064','lexi-content-ref-27502503','lexi-content-ref-20609140','lexi-content-ref-AAP.2018'])">Ref</a></span>). Although lower doses (10 to 15 mg/kg/day) have been suggested previously by experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10886135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10886135'])">Ref</a></span>) and by the manufacturer, they are associated with extended treatment durations and/or potentially lower cure rates and have fallen out of favor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2018','lexi-content-ref-AAP.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2018','lexi-content-ref-AAP.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Ultramicrosize: Oral: 10 to 15 mg/kg/day once daily (maximum daily dose: 750 mg/<b>day</b>) for 6 to 8 weeks or until fungal cultures clear; in some cases, treatment up to 12 to 18 weeks may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17876261','lexi-content-ref-25403034','lexi-content-ref-20609140','lexi-content-ref-AAP.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17876261','lexi-content-ref-25403034','lexi-content-ref-20609140','lexi-content-ref-AAP.2018'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112851"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51112852"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: Use is contraindicated in hepatic failure.</p></div>
<div class="block doa drugH1Div" id="F177525"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8502" href="/d/html/8502.html" rel="external">see "Griseofulvin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64502832-afb2-4634-b4cc-9964152e6c0b">Onychomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onychomycosis (</b>
<b>alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients unable to use preferred agents due to the increased risk for adverse effects, reduced efficacy, and need for prolonged treatment duration with griseofulvin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409999','lexi-content-ref-28707751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409999','lexi-content-ref-28707751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Microsize: Oral:</b> 1 g/day in single or divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18478357','lexi-content-ref-7632064','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18478357','lexi-content-ref-7632064','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ultramicrosize: Oral:</b> 750 mg/day in single or divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18478357','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18478357','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Duration: </b>&gt;4 months (eg, 6 to 9 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409999'])">Ref</a></span>)) for fingernail and &gt;6 months (eg, 12 to 18 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409999'])">Ref</a></span>)) for toenail infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15c0a5bc-b04b-4bce-808a-eba28afcd673">Tinea infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dermatophyte folliculitis (tinea barbae, Majocchi granuloma) (alternative agent): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Microsize: Oral:</b> 500 mg/day in single or divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14739517','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14739517','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ultramicrosize: Oral:</b> 375 mg/day in single or divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: 4 to 8 weeks or until clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14739517','lexi-content-ref-22435879','lexi-content-ref-Jackson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14739517','lexi-content-ref-22435879','lexi-content-ref-Jackson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea capitis: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Microsize: Oral:</b> 500 mg to 1 g/day in single or divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24336943','lexi-content-ref-18459518','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24336943','lexi-content-ref-18459518','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ultramicrosize: Oral:</b> 375 to 750 mg/day in single or divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18459518','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18459518','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: 4 to 6 weeks according to the manufacturer’s labeling, but based on experience in pediatrics, up to 12 weeks may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18478357','lexi-content-ref-18459518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18478357','lexi-content-ref-18459518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea corporis/tinea cruris (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Alternative treatment for patients with extensive skin involvement or in whom topical therapy failed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Microsize: Oral:</b> 500 mg to 1 g/day in single or divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2194715','lexi-content-ref-18478357','lexi-content-ref-18204748','lexi-content-ref-8089640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2194715','lexi-content-ref-18478357','lexi-content-ref-18204748','lexi-content-ref-8089640'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ultramicrosize: Oral:</b> 375 to 500 mg/day in single or divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.1','lexi-content-ref-18478357','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.1','lexi-content-ref-18478357','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2194715','lexi-content-ref-18478357','lexi-content-ref-18204748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2194715','lexi-content-ref-18478357','lexi-content-ref-18204748'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea pedis (labeled use)/tinea manuum (off-label use) (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Alternative treatment for patients with extensive skin involvement or in whom topical therapy failed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.1'])">Ref</a></span>). Griseofulvin has lower efficacy for tinea pedis than other systemic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18478357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18478357'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Microsize: Oral:</b> 1 g/day in single or divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18478357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18478357'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ultramicrosize: Oral:</b> 750 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18478357','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18478357','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: 4 to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18478357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18478357'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991858"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989154"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in hepatic failure.</p></div>
<div class="block adr drugH1Div" id="F177494"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme (Hidajat 2014), severe dermatological reaction (including Stevens-Johnson syndrome, toxic epidermal necrolysis) (Araujo 1990), skin photosensitivity (Araujo 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Porphyria (Araujo 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (Araujo 1990), anorexia (Araujo 1990), diarrhea (Araujo 1990), epigastric discomfort, flatulence (Araujo 1990), gastrointestinal hemorrhage, nausea (Araujo 1990), oral candidiasis, vomiting (Araujo 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (Bhat 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of hemostatic components of blood, leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hepatotoxicity, hyperbilirubinemia, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, drug reaction with eosinophilia and systemic symptoms (Maiolo 2016), hypersensitivity reaction (Quero 1960), serum sickness (Araujo 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, dizziness (Araujo 1990), fatigue (Araujo 1990), headache (Araujo 1990), insomnia (Araujo 1990), paresthesia, peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Exacerbation of systemic lupus erythematosus (Madhok 1985), lupus erythematosus, lupus-like syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Bhat 2016), nephrosis</p></div>
<div class="block coi drugH1Div" id="F177508"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to griseofulvin or any component of the formulation; hepatic failure; porphyria; pregnancy</p></div>
<div class="block war drugH1Div" id="F177491"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Leukopenia has been reported (rare); discontinue therapy if granulocytopenia occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: May cause jaundice and elevated liver function tests or bilirubin (may be serious or even fatal); monitor hepatic function and discontinue therapy if necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Penicillin allergy: Hypersensitivity cross reaction between penicillins and griseofulvin is possible, however, known penicillin-sensitive patients have been treated successfully without complications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Avoid exposure to intense sunlight to prevent photosensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: Severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) have been reported (may be serious or even fatal); discontinue use if severe skin reactions occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lupus erythematosus: Development of lupus erythematosus, lupus-like syndromes or exacerbation of existing lupus erythematosus has been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use for the prophylaxis of fungal infections has not been established; not effective for the treatment of tinea versicolor (pityriasis versicolor).</p></div>
<div class="block dosfc drugH1Div" id="F22123828"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Microsized formulations: 500 mg tablet and suspension</p>
<p style="text-indent:-2em;margin-left:2em;">Ultramicrosize formulation: 125 mg and 250 mg tablets</p></div>
<div class="block foc drugH1Div" id="F177502"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (118 mL, 120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F177487"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F177510"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Griseofulvin Microsize Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $0.65 - $2.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Griseofulvin Microsize Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $8.80 - $9.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Griseofulvin Ultramicrosize Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $4.69 - $4.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $6.00 - $6.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612945"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Microsize oral suspension, tablets: Administer with a fatty meal (eg, whole milk, ice cream, peanut butter) to increase absorption; shake suspension well before use.</p>
<p style="text-indent:-2em;margin-left:4em;">Ultramicrosize tablets: May be swallowed whole or crushed and sprinkled onto 1 tablespoonful of applesauce and swallowed immediately without chewing.</p></div>
<div class="block adm drugH1Div" id="F177505"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with a fatty meal to increase absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-RedBook.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-RedBook.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Additional formulation-specific administration information:</p>
<p style="text-indent:-2em;margin-left:4em;">Ultramicrosize formulation (125 mg and 250 mg tablets): May be swallowed whole or crushed and sprinkled onto 1 tablespoonful of applesauce and swallowed immediately without chewing.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Shake well before use.</p></div>
<div class="block sts drugH1Div" id="F15826199"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53567155"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of tinea infections of the skin and hair caused by susceptible species of <i>Microsporum</i>, <i>Epidermophyton</i>, or <i>Trichophyton</i> when lesions are unresponsive to topical antifungal therapy (FDA approved in ages &gt;2 years and adults)</p></div>
<div class="block mst drugH1Div" id="F56381727"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F177554"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F177496"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): Griseofulvin may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May decrease the serum concentration of Griseofulvin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbocisteine: Griseofulvin may enhance the adverse/toxic effect of Carbocisteine. Specifically, griseofulvin may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Griseofulvin may enhance the adverse/toxic effect of Chlorprothixene. Specifically, the risk for acute porphyrias may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Griseofulvin may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Griseofulvin may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing griseofulvin to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: Griseofulvin may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Griseofulvin may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F177516"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Ethanol: Concomitant ethanol use may cause rare disulfiram reaction. Management: Monitor patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Food: Griseofulvin concentrations may be increased if taken with food, especially with high-fat meals. Management: Take with a fatty meal (peanuts or ice cream) to increase absorption, or with food or milk to avoid GI upset.</p></div>
<div class="block rep_considerations drugH1Div" id="F49307058"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Females of reproductive potential should use affective contraception during therapy (estrogen containing contraceptives may be less effective). Men should avoid fathering a child for at least 6 months after therapy.</p></div>
<div class="block pri drugH1Div" id="F4293494"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Griseofulvin crosses the placenta (Pacifici 2006). Adverse events have been observed in humans (two cases of conjoined twins); therefore, use during pregnancy is contraindicated.</p></div>
<div class="block mopp drugH1Div" id="F53567132"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver function (AST, ALT, bilirubin) if treatment duration &gt;8 weeks (<i>Red Book </i>[AAP 2018]); signs of hepatotoxicity with prolonged use (Ely 2014); CBC (periodically)</p></div>
<div class="block pha drugH1Div" id="F177490"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits fungal cell mitosis at metaphase; binds to human keratin making it resistant to fungal invasion</p></div>
<div class="block phk drugH1Div" id="F177507"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Ultramicrosize griseofulvin absorption is almost complete; absorption of microsize griseofulvin is variable (27% to 72% of an oral dose); enhanced by ingestion of a fatty meal (GI absorption of ultramicrosize is ~1.5 times that of microsize); absorbed from the duodenum</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Deposited in the keratin layer of skin, hair, and nails; concentrates in liver, fat, and skeletal muscles; V<sub>d</sub>: ~1.5  L (Vozeh 1988)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 9 to 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt;1% as unchanged drug); feces (~33%); perspiration</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F177511"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Grisovin fp</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Grisovin fp</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Griseomed | Grisovin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Griseostatin | Grisovin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Afuvin | Fisovin | Fulcinex | Grifulvin | Griso | Grisofulvin | Grisotin | Grisovin fp | Japcin | Nidovin | Refulvin | Risovin | Seovin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Griseofulvine | Griseopharm</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Sporostatin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fulcin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Fulvin | Griseo | Griseofulvine</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Griseofulvina</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Grisovin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Gricin | Grizeofulvin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Fulcin s | Gricin | Griseo von CT | Likuden m | Polygris</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Fulkain | Griseofulvina | Grisovin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Grisovin fp | H.G. Griseofulvin | Sporostatin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Griseo | Medofulvin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Fulvin | Griseovin | Grisofulvin fp | Ultrafulvin | Ultrafuvin | Ultragriseofulvin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Greosin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Griscor</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Grisovin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fulcine | Grisefuline</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fulsovin</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Letavin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Grisenova</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cp griseo | Fungivin | Fuvin | Geovite | Grifucin | Griseostatin | Grisofen | Grisovin | Grivin | Syngriseolin | U fulvin | U-d</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Gricin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Biogrisin | Fulcin | Griseofort | Grivin | Microfulvin-500 | Mycostop | Rexavin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Grifulin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Dermonorm | Ecovin | Fluvin | Fulvin-m | Fungal | Fungivin | G win | Geovin | Griderm | Grifulvin | Gris-o.d. | Grisactin | Griseoderm o.d. | Grisojet | Grisomed | Grisonorm | Grisoral | Grisovin fp | Grisure | Idifulvin | Myconorm | Nufulvin | Profulvin | Ulvin | Walavin | Zorbax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Grisovina fp</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Griseovin | Grisovin | Sporofulvin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fulcin f | Fulvistatin Uf | Grifuluvin f p | Griscelsin | Griseofulvin sg | Grisetin | Grisovin fp | Grisovin sankyo | Guservin fp | Poncyl fp</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Asfulvin | Biofulvin | Dermavin | Fulvin | Fungivin | Grisactin | Griseben | Griseofil | Griseofred | Griso | Grisofulvin | Grisolab | Medifulvin | Umifulvin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Fulvicin | Pongyl-v</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Fulcin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Grisefuline | Griseofulvine | Seovine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Gricin | Griseo | Grisovin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Gricin | Grisefuline | Griseo | Grisovin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Fulcine | Grisefuline | Griseo | Griseopharm</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fulcin forte | Fulvina p/g | Grisovin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dynafucin | Fulcin | Grifulvil | Griseofulva | Grisovin fp | Grisuvin | Grivin | Hexene | Krisovin | Medofulvin | Myconil | Suvin | Tinovin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Biomesovin | Crivicin | Fulcimex | Gauze griseofulvin | Genevin | Grenin | Grisam | Griseoval | Grisoforis | Hanbfulvin | Mavin | Mekophar griseofulvin | Microstall | Nelpharm griseofulvin | Nostulvin | Nusovin | Phomvin | Refucil | Zonason griseofulvin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Griseofulv | Griseofulvine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fungivin | Griseofulvin essential generics</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Grisovin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Grisovin fp | Sporostatin Uf</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Grisovin fp</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Fungivin | Griful | Grifulvin | Grisol | Grisovin fp | Grivin | Gryso</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Gricin | Grisefuline</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fulvicin p/g | Fulvicin-uf | Grifulvin v | Gris-Peg | Grisactin | Grisactin ultra | Griseofulvin micro | Griseofulvin ultramicrosize | Ultramicrosize griseofulvin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Grisomicon | Grisovin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ultragriseofulvin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fulcin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Fulcin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Grisuvin | Krisovin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Grisovin</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Grivin forte</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aofen | Brifulvin | Fucin | Fuga | Fuga fp | Fugafec | Fulvin | Fulvinbemed | Fungin | Fungivin | Funsevin | Fusovin | Fuvin | Graovin | Gravier | Gresio | Gresofuvin | Grevin | Grifulvin | Grimax | Griscofulvin | Griseo-med | Griseomed | Grisflavin | Grisin | Griso | Grisovex | Grisovin | Grisovin fp | Grisvin | Grivin | K.b.vinecin | Mycovin | Mycoxyl | Neofulvin | Newfulvin | Seapfulvin | Trivanex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Griseofulvine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Gefulvin | Grifulvin | Grisovin fp</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fulcin | Fulvistatin Uf | Fungacin | Fusofucin | Fuyou | Grifucin | Grifulcin | Grisen | Grisomin | Grisovin | Gruvin | Guservin | Honseofulvin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agofulvin | Asfulvin | Dermoren | Grisactin | Griseben | Griseofil | Griseosim 500 | Griso 500 | Medofulvin | Zifam gris</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Grisovin fp</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Grisovin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Gifuldin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Microcidal</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Dermofulvin | Dynafucin | Griseben | Griseofil | Griseosim | Grisoral</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Grisoral</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17876261">
<a name="17876261"></a>Ali S, Graham TA, Forgie SE. The Assessment and Management of Tinea Capitis in Children. <i>Pediatr Emerg Care</i>. 2007; 23(9):662-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/17876261/pubmed" id="17876261" target="_blank">17876261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25409999">
<a name="25409999"></a>Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. <i>Br J Dermatol</i>. 2014;171(5):937-958. doi:10.1111/bjd.13358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/25409999/pubmed" id="25409999" target="_blank">25409999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2018">
<a name="AAP.2018"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2260345">
<a name="2260345"></a>Araujo OE, Flowers FP, King MM. Griseofulvin: a new look at an old drug. <i>DICP</i>. 1990;24(9):851-854. doi:10.1177/106002809002400912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/2260345/pubmed" id="2260345" target="_blank">2260345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atanasovski.2011">
<a name="Atanasovski.2011"></a>Atanasovski M, El Tal AK, Hamzavi F, Mehregan DA. Neonatal dermatophytosis: report of a case and review of the literature. <i>Pediatr Dermatol</i>. 2011;28(2):185-188.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25420079">
<a name="25420079"></a>Bhat ZY, Sharma N, Pillai U, Singh A. Unusual cause and presentation of collapsing focal segmental glomerulosclerosis. <i>Am J Ther</i>. 2016;23(3):e957-e960. doi:10.1097/MJT.0000000000000115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/25420079/pubmed" id="25420079" target="_blank">25420079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14739517">
<a name="14739517"></a>Bonifaz A, Ramírez-Tamayo T, Saúl A. Tinea barbae (tinea sycosis): experience with nine cases. <i>J Dermatol</i>. 2003;30(12):898-903. doi:10.1111/j.1346-8138.2003.tb00345.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/14739517/pubmed" id="14739517" target="_blank">14739517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2018">
<a name="Bradley.2018"></a>Bradley JS, Nelson JD, Barnett ED, Cantey JB, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 24th ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2194715">
<a name="2194715"></a>del Palacio Hernandez A, López Gómez S, González Lastra F, Moreno Palancar P, Iglesias Díez L. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. <i>Clin Exp Dermatol</i>. 1990;15(3):210-216. doi:10.1111/j.1365-2230.1990.tb02074.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/2194715/pubmed" id="2194715" target="_blank">2194715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24336943">
<a name="24336943"></a>El-Khalawany M, Shaaban D, Hassan H, et al. A multicenter clinicomycological study evaluating the spectrum of adult tinea capitis in Egypt. <i>Acta Dermatovenerol Alp Pannonica Adriat</i>. 2013;22(4):77-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/24336943/pubmed" id="24336943" target="_blank">24336943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25403034">
<a name="25403034"></a>Ely JW, Rosenfeld S, Seabury Stone M. Diagnosis and management of tinea infections. <i>Am Fam Physician</i>. 2014;90(10):702-710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/25403034/pubmed" id="25403034" target="_blank">25403034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15520113">
<a name="15520113"></a>Fleece D, Gaughan JP, Aronoff SC. Griseofulvin Versus Terbinafine in the Treatment of Tinea Capitis: A Meta-Analysis of Randomized, Clinical Trials. <i>Pediatrics</i>. 2004;114(5):1312-1315.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/15520113/pubmed" id="15520113" target="_blank">15520113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234064">
<a name="25234064"></a>Fuller LC, Barton RC, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the management of tinea capitis 2014. <i>Br J Dermatol</i>. 2014;171(3):454-463. doi:10.1111/bjd.13196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/25234064/pubmed" id="25234064" target="_blank">25234064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6822943">
<a name="6822943"></a>Ginsburg CM, McCracken GH Jr, Petruska M, et al. Effect of Feeding on Bioavailability of Griseofulvin in Children. <i>J Pediatr</i>. 1983;102(2):309-311.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/6822943/pubmed" id="6822943" target="_blank">6822943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.1">
<a name="Goldstein.1"></a>Goldstein AO, Goldstein BG. Dermatophyte (tinea) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actavis.1">
<a name="Actavis.1"></a>Griseofulvin oral suspension [prescribing information]. Parsippany, NJ: Actavis Pharma Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Griseofulvin tablet (microsize) [prescribing information]. Princeton, NJ: Sandoz Inc.; December 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chartwell.1">
<a name="Chartwell.1"></a>Griseofulvin tablet (ultramicrosize) [prescribing information]. Congers, NY: Chartwell Pharmaceuticals, LLC; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18478357">
<a name="18478357"></a>Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. <i>Mycopathologia</i>. 2008a;166(5-6):353-367. doi:10.1007/s11046-008-9109-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/18478357/pubmed" id="18478357" target="_blank">18478357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18459518">
<a name="18459518"></a>Gupta AK, Cooper EA, Bowen JE. Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis. <i>J Drugs Dermatol</i>. 2008b;7(4):369-372.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/18459518/pubmed" id="18459518" target="_blank">18459518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27502503">
<a name="27502503"></a>Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. <i>Mycopathologia</i>. 2017;182(1-2):127-141. doi:10.1007/s11046-016-0045-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/27502503/pubmed" id="27502503" target="_blank">27502503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25246464">
<a name="25246464"></a>Hidajat C, Loi D. Drug-mediated rash: erythema multiforme versus Stevens-Johnson syndrome. <i>BMJ Case Rep</i>. 2014;2014:bcr2014205543. doi:10.1136/bcr-2014-205543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/25246464/pubmed" id="25246464" target="_blank">25246464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10886135">
<a name="10886135"></a>Higgins EM, Fuller LC, and Smith CH. Guidelines for the management of tinea capitis. British Association of Dermatologists. <i>Br J Dermatol. </i>2000;143(1):53-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/10886135/pubmed" id="10886135" target="_blank">10886135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7632064">
<a name="7632064"></a>Hofmann H, Bräutigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. <i>Arch Dermatol</i>. 1995;131(8):919-922. doi:10.1001/archderm.131.8.919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/7632064/pubmed" id="7632064" target="_blank">7632064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22435879">
<a name="22435879"></a>Ilkit M, Durdu M, Karakaş M. Majocchi's granuloma: a symptom complex caused by fungal pathogens. <i>Med Mycol</i>. 2012;50(5):449-457. doi:10.3109/13693786.2012.669503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/22435879/pubmed" id="22435879" target="_blank">22435879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jackson.1">
<a name="Jackson.1"></a>Jackson JD. Infectious folliculitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20609140">
<a name="20609140"></a>Kakourou T and Uksal U. Guidelines for the management of tinea capitis in children. <i>Pediatr Dermatol. </i>2010;27(3):226-228. doi:10.1111/j.1525-1470.2010.01137.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/20609140/pubmed" id="20609140" target="_blank">20609140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3249685">
<a name="3249685"></a>Kawabe Y, Mizuno N, Miwa N, et al. Photosensitivity Induced by Griseofulvin. <i>Photodermatol</i>. 1988;5(6):272-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/3249685/pubmed" id="3249685" target="_blank">3249685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18204748">
<a name="18204748"></a>Khaled A, Chtourou O, Zeglaoui F, Fazaa B, Jones M, Kamoun MR. Tinea faciei: a report on four cases. <i>Acta Dermatovenerol Alp Pannonica Adriat</i>. 2007;16(4):170-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/18204748/pubmed" id="18204748" target="_blank">18204748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28707751">
<a name="28707751"></a>Kreijkamp-Kaspers S, Hawke K, Guo L, et al. Oral antifungal medication for toenail onychomycosis. <i>Cochrane Database Syst Rev</i>. 2017;7(7):CD010031. doi:10.1002/14651858.CD010031.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/28707751/pubmed" id="28707751" target="_blank">28707751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lecky.1990">
<a name="Lecky.1990"></a>Lecky BR. Griseofulvin-Induced Neuropathy. <i>Lancet</i>. 1990;335(8683):230-231.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21803962">
<a name="21803962"></a>Lewis RE. Current Concepts in Antifungal Pharmacology. <i>Mayo Clin Proc.</i> 2011;86(8):805-817.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/21803962/pubmed" id="21803962" target="_blank">21803962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12000378">
<a name="12000378"></a>Lipozencic J, Skerlev M, Orofino-Costa R, et al. A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study of Oral Terbinafine and Open-Label, High-Dose Griseofulvin in Children With Tinea Capitis Due to <i>Microsporum</i> Species. <i>Br J Dermatol</i>. 2002;146(5):816-823.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/12000378/pubmed" id="12000378" target="_blank">12000378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19487765">
<a name="19487765"></a>Lorch Dauk KC, Comrov E, Blumer JL, O'Riordan MA, Furman LM. Tinea capitis: predictive value of symptoms and time to cure with griseofulvin treatment. <i>Clin Pediatr (Phila)</i>. 2010;49(3):280-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/19487765/pubmed" id="19487765" target="_blank">19487765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3926142">
<a name="3926142"></a>Madhok R, Zoma A, Capell H. Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin. <i>Br Med J (Clin Res Ed)</i>. 1985;291(6490):249-250. doi:10.1136/bmj.291.6490.249<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/3926142/pubmed" id="3926142" target="_blank">3926142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27556061">
<a name="27556061"></a>Maiolo C, Ross C, Ibbetson J, Kearney D. Griseofulvin associated with drug reaction with eosinophilia and systemic symptoms (DRESS). <i>JAAD Case Rep</i>. 2016;2(4):315-316. doi:10.1016/j.jdcr.2016.05.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/27556061/pubmed" id="27556061" target="_blank">27556061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22468173">
<a name="22468173"></a>Michaels BD, Del Rosso JQ. Tinea capitis in infants: recognition, evaluation, and management suggestions. <i>J Clin Aesthet Dermatol</i>. 2012;5(2):49-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/22468173/pubmed" id="22468173" target="_blank">22468173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mion.1989">
<a name="Mion.1989"></a>Mion G, Verdon R, Le Gulluche Y, et al. Fatal Toxic Epidermal Necrolysis After Griseofulvin. <i>Lancet</i>. 1989;2(8675):1331.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16502764">
<a name="16502764"></a>Pacifici GM. Placental Transfer of Antibiotics Administered to the Mother: A Review. <i>Int J Clin Pharmacol Ther</i>. 2006;44(2):57-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/16502764/pubmed" id="16502764" target="_blank">16502764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431130">
<a name="12431130"></a>Pomeranz AJ, Sabnis SS. Tinea Capitis: Epidemiology, Diagnosis and Management Strategies. <i>Paediatr Drugs</i>. 2002;4(12):779-783.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/12431130/pubmed" id="12431130" target="_blank">12431130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14435514">
<a name="14435514"></a>Quero R. Allergic reaction to griseofulvin. <i>J Invest Dermatol</i>. 1960;34:283-284. doi:10.1038/jid.1960.48<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/14435514/pubmed" id="14435514" target="_blank">14435514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2913964">
<a name="2913964"></a>Rampini E, Schiazza L, Occella C, et al. Falsely elevated urinary level of vanillylmandelic acid induced by griseofulvin. <i>Arch Dermatol</i>. 1989;125(2):269-270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/2913964/pubmed" id="2913964" target="_blank">2913964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RedBook.2015">
<a name="RedBook.2015"></a>
<i>Red Book®: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed, Kimberlin DW, ed. American Academy of Pediatrics, 2015;712-714; 832t.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16804437">
<a name="16804437"></a>Sethi A, Antaya R. Systemic Antifungal Therapy for Cutaneous Infections in Children. <i>Pediatr Infect Dis J</i>. 2006;25(7):643-644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/16804437/pubmed" id="16804437" target="_blank">16804437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23575220">
<a name="23575220"></a>Shemer A, Plotnik IB, Davidovici B, et al. Treatment of tinea capitis - griseofulvin versus fluconazole - a comparative study. <i>J Dtsch Dermatol Ges</i>. 2013;11(8):737-741.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/23575220/pubmed" id="23575220" target="_blank">23575220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242915">
<a name="15242915"></a>Sladden MJ, Johnston GA. Common Skin Infections in Children. <i>BMJ</i>. 2004;329(7457):95-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/15242915/pubmed" id="15242915" target="_blank">15242915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9496407">
<a name="9496407"></a>Trepanier EF, Amsden GW. Current Issues in Onchomycosis. <i>Ann Pharmacother</i>. 1998;32(2):204-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/9496407/pubmed" id="9496407" target="_blank">9496407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8089640">
<a name="8089640"></a>Voravutinon V. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. <i>J Med Assoc Thai</i>. 1993;76(7):388-393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/8089640/pubmed" id="8089640" target="_blank">8089640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3191648">
<a name="3191648"></a>Vozeh S, Schmidlin O, Taeschner W. Pharmacokinetic Drug Data. <i>Clin Pharmacokinetics</i>. 1988;15(4):254-282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/3191648/pubmed" id="3191648" target="_blank">3191648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3890481">
<a name="3890481"></a>Yang DJ, Rankin GO. Nephrotoxicity of Antifungal Agents. <i>Adverse Drug React Acute Poisoning Rev</i>. 1985;4(1):37-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/3890481/pubmed" id="3890481" target="_blank">3890481</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13342 Version 266.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
